The soft tissue allografts market size is projected to reach US$ 6,748.28 million by 2031 from US$ 4,088.49 million in 2024. The market is expected to register a CAGR of 7.4% during 2024–2031. The development of customized grafts is likely to bring in new market trends during the forecast period.
Sports-related injuries, particularly in athletes and physically active individuals, often involve soft tissue damage. Several injuries are being reported worldwide due to physical activities. For instance, as per the National Safety Council, in 2023, 3.7 million people in the US were treated in emergency departments for injuries. Exercise injuries and exercise equipment injuries increased by 8% from 2022 to 2023; the number of injuries increased from 445,642 in 2022 to 482,886 in 2023. The 15–24 age group had the highest injury rate; more males are injured than females (276,377 males vs. 206,381 females), and 90% of injured individuals are treated in emergency departments. According to the National Health Service (NHS), ~2 million people in the UK are hospitalized in “accident & emergency” departments due to sports injuries every year. As per Howden’s Men’s European Football Injury Index, 4,123 injuries were reported across the five major European Leagues during the 2023–2024 season, a 4% increase from the previous season (2022–2023). These injuries amounted to EUR 732.02 million (US$ 798.70 million), reflecting a 5% rise in overall injury-related expenses.
Injuries caused during sports and physical activities increase the demand for soft tissue allografts to repair or replace damaged tissues. When injuries are too extensive for the body to heal through inherant repair mechanism or conventional treatment approaches, soft tissue allografts are used to repair or reconstruct the damaged tissue. Allografts have been in use routinely in sports medicine since the 1980s. Soft tissue allografts are perceived as an important substitute tissue for the reconstruction of torn menisci, deficient ligaments, and osteochondral defects during knee surgeries. These procedures allow for more standardized grafts in reconstructive surgeries, specifically in relation to graft diameter, integrity, shape, and reproducibility. Moreover, this technique has emerged as an attractive alternative to autografts among surgeons due to shorter operating times, greater operating efficiency, and reduced donor site morbidity. Thus, the soft tissue allografts market growth can be attributed to the rising incidence of sports injuries and trauma.
The soft tissue allografts market is rapidly expanding due to the increasing aging population, and the rising incidence of sports injuries and trauma. Prominent players operating in the market are focusing on innovation and collaboration for enhanced product availability. However, the high cost of procedures hinders the soft tissue allografts market growth.
Sports-related injuries, particularly in athletes and physically active individuals, often involve soft tissue damage. Several injuries are being reported worldwide due to physical activities. For instance, as per the National Safety Council, in 2023, 3.7 million people in the US were treated in emergency departments for injuries. Exercise injuries and exercise equipment injuries increased by 8% from 2022 to 2023; the number of injuries rose from 445,642 in 2022 to 482,886 in 2023. The 15–24 age group had the highest injury rate; more males are injured than females (276,377 males vs. 206,381 females), and 90% of injured individuals are treated in emergency departments. According to the National Health Service (NHS), ~2 million people in the UK are hospitalized in “accident & emergency” departments due to sports injuries every year. As per Howden’s Men’s European Football Injury Index, 4,123 injuries were reported across the five major European Leagues during the 2023–2024 season, a 4% increase from the previous season (2022–2023). These injuries amounted to EUR 732.02 million (US$ 798.70 million), reflecting a 5% rise in overall injury-related expenses.
Injuries caused during sports and physical activities increase the demand for soft tissue allografts to repair or replace damaged tissues. Soft tissue allografts are used to repair or reconstruct the damaged tissue when injuries are too extensive for the body to heal through an inherent repair mechanism or conventional treatment approaches. Allografts have been in use routinely in sports medicine since the 1980s. Soft tissue allografts are perceived as an important substitute tissue for the reconstruction of torn menisci, deficient ligaments, and osteochondral defects during knee surgeries. These procedures allow for more standardized grafts in reconstructive surgeries, specifically in relation to graft diameter, integrity, shape, and reproducibility. Moreover, this technique has emerged as an attractive alternative to autografts among surgeons due to shorter operating times, greater operating efficiency, and reduced donor site morbidity. Thus, the soft tissue allografts market growth can be attributed to the rising incidence of sports injuries and trauma.
Several companies are focusing on developing innovative products through extensive research. These products are likely to offer superior treatment outcomes compared to the existing products. For instance, AlloSource is one of the largest allograft providers in the US, offering innovative cellular and tissue products to help healthcare providers heal their patients. In May 2023, the company announced the launch of AlloMend Duo Acellular Dermal Matrix (ADM), a natural solution for soft tissue reconstruction. In June 2024, Axogen, Inc., a global leader in developing innovative surgical solutions for peripheral nerve injuries, announced the launch of its new product named Avive+ Soft Tissue Matrix. This product is intended for use as a soft tissue barrier; it is a resorbable, multi-layer amniotic membrane allograft designed to provide temporary protection and tissue separation during the critical phase of peripheral nerve healing. In February 2022, Amnio Technology, a global leader in amniotic tissue allograft development and distribution, announced the launch of two new products in its PalinGen membrane line: the PalinGen Dual-Layer Membrane and the Dual Layer PalinGen X-Membrane. Similar to all products in the PalinGen family, these new allografts are minimally modified and are intended for homologous use. The new soft tissue allograft products launched in recent years are designed to meet changing patient needs, improve recovery times, reduce complications, and address various clinical indications. Launching more such products is expected to create significant growth opportunities for the soft tissue allograft market in the coming years.
Key segments that contributed to the derivation of the soft tissue allografts market analysis are type, application, and end user.
The geographic scope of the soft tissue allografts market report mainly focuses on five regions: North America, Asia Pacific, Europe, South & Central America, and the Middle East & Africa. In terms of revenue, North America dominated the market in 2024. It is expected to continue its dominance in the global market during the forecast period. The US is the largest market for soft tissue allografts in the world. It represents a significant portion of the soft tissue allografts market, with a notable number of procedures performed annually. According to a study titled “New Device Inspired by Python Teeth Doubles Strength of Rotator Cuff,” published in 2024, more than 600,000 rotator cuff procedures are performed yearly in the US. As per the American Orthopedic Society for Sports Medicine, nearly 100,000 to 250,000 ACL ruptures are reported in the country annually. Several tissue injuries have received significant importance, increasing awareness about soft tissue injuries and their treatment among athletes. In May 2023, AlloSource announced the introduction of AlloMend Duo Acellular Dermal Matrix (ADM), a natural solution designed for soft tissue reconstruction. It is one of the largest nonprofit providers of allografts in the US, known for developing innovative cellular and tissue products to aid surgeons in healing their patients. ADM was developed to assist surgeons in repairing and reconstructing soft tissue defects, offering long-term structural support. This deep reticular dermal allograft integrates with the surrounding tissue, serving as a scaffold that encourages cell repopulation and regeneration of natural host tissues. Its flexible and pliable characteristics make it ideal for various medical procedures that demand strength and biocompatibility in a human regenerative tissue matrix, allowing for precision placement and optimal handling.
The regional trends and factors influencing the Soft Tissue Allografts Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses Soft Tissue Allografts Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.
| Report Attribute | Details |
|---|---|
| Market size in 2024 | US$ 4,088.49 Million |
| Market Size by 2031 | US$ 6,748.28 Million |
| Global CAGR (2024 - 2031) | 7.4% |
| Historical Data | 2021-2023 |
| Forecast period | 2024-2031 |
| Segments Covered |
By Type
|
| Regions and Countries Covered | North America
|
| Market leaders and key company profiles |
The Soft Tissue Allografts Market market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.
Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.
Major Companies operating in the Soft Tissue Allografts Market are:
Disclaimer: The companies listed above are not ranked in any particular order.
The soft tissue allografts market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. Below are a few of the key development witnessed in the soft tissue allografts market:
The "Soft Tissue Allografts Market Size and Forecast (2021–2031)" report provides a detailed analysis of the market covering below areas:
The List of Companies - Soft Tissue Allografts Market
The soft tissue allografts market value is expected to reach US$ 6,748.28 million by 2031.
The market is expected to register a CAGR of 7.4% during 2024–2031.
The development of customized grafts is likely to emerge as a new growth trend in the market in the coming years.
Zimmer Biomet Holdings Inc, Conmed Corp, Stryker Corp, Smith & Nephew Plc, Integra LifeSciences Holdings Corp, Arthrex Inc, AbbVie Inc, Organogenesis Inc., Dentsply Sirona Inc, and Axogen Corporation are among the key players operating in the market.
North America dominated the market in 2024.
An increasing aging population, and the rising incidence of sports injuries and trauma are among the most significant factors fueling the market growth.